Anlon Healthcare IPO Subscription Status

The Anlon Healthcare IPO continued to attract strong demand on its second day of subscription (28th August 2025), getting subscribed 3.30 times by 5:00 PM.

• Qualified Institutional Buyers (QIBs): 1.01 times
• Non-Institutional Investors (NIIs): 2.09 times
• Retail Individual Investors (RIIs): 22.33 times

By the end of Day 2, the IPO had received bids for 4,39,44,948 shares compared to the 1,33,00,000 shares available for subscription.

Day-wise subscription trend:

• Day 1 (27th August 2025): 1.69x
• Day 2 (28th August 2025): 3.30x

About Anlon Healthcare Limited

Established in 2013, Anlon Healthcare Limited is a fast-growing chemical and pharmaceutical manufacturer engaged in the production of:

1. High-purity pharmaceutical intermediates – raw materials used for manufacturing APIs.
2. Active Pharmaceutical Ingredients (APIs) – used in formulations such as tablets, capsules, syrups, ointments, nutraceuticals, personal care, and veterinary products.

The company has developed a diverse product portfolio including:

• 65 commercial products in the market
• 28 products at pilot stage
• 49 products under laboratory testing

Notably, Anlon Healthcare is among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, a widely used API for pain management in cases like arthritis, frozen shoulder, back pain, dental issues, and post-surgery recovery.

As of 31st January 2025, the company employed 105 full-time staff (excluding trainees) along with 8 contract workers across its facilities.

Anlon Healthcare Financial Performance

The company’s financial track record shows a mix of growth and volatility:

• Revenue (FY 2024): ₹66.69 crore vs. ₹113.12 crore in FY 2023
• Net Profit (FY 2024): ₹9.66 crore vs. ₹5.82 crore in FY 2023
• Observation: While revenue fell 41% YoY, profit margins improved due to better cost control and higher-value product sales.

The company continues to invest in R&D and pilot-stage products, which may support future revenue growth.

Anlon Healthcare IPO GMP

As of Thursday, 28th August 2025, the Grey Market Premium (GMP) for Anlon Healthcare IPO stood at ₹6 per share.

This indicates that the shares are trading at around ₹97 in the grey market, compared to the issue price of ₹91, reflecting investor optimism with a 6.6% premium.